Adding a Kinase to Pembrolizumab May Increase CLL Treatment Efficacy
Adding BCR kinase inhibitor ibrutinib or idelalisib to monoclonal antibody pembrolizumab increases treatment efficacy in CLL with Richter transformation.
Read MoreAdding BCR kinase inhibitor ibrutinib or idelalisib to monoclonal antibody pembrolizumab increases treatment efficacy in CLL with Richter transformation.
Read MoreNipocalimab showed a significant decrease in Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.
Read MoreIn SSc plus mild pulmonary vascular disease, early treatment with ambrisentan effectively prevented pulmonary vascular disease progress and development of PAH.
Read MoreThe following is a summary of “State of patient reported outcome measures in rheumatology,”...
Read MoreUpadacitinib 15 mg demonstrated convincing results as a treatment for giant cell arteritis in the phase 3 SELECT-GCA trial.
Read More